FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Read more: https://www.cancernetwork.com/view/fda-approves-crizotinib-for-pediatric-alk-alcl-indication